1
|
Tjokrowidjaja A, Browne L, Soudy H. External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. Asia Pac J Clin Oncol 2021; 18:e280-e288. [PMID: 34811927 DOI: 10.1111/ajco.13689] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2021] [Accepted: 09/23/2021] [Indexed: 12/24/2022]
Abstract
AIM The American Joint Committee on Cancer (AJCC) melanoma staging system eighth edition (AJCC-8) was recently released to provide accurate staging reflecting advances in the treatment of melanoma. Using population registry data, this study independently validates and compares the prognostic performance of AJCC-8 to the seventh edition (AJCC-7). METHODS We extracted patient-, tumor-related, and survival data from the SEER-18 registry between 2010 and 2015. To assess overall survival (OS) and cancer-specific survival (CSS) for AJCC-7 and AJCC-8, we performed Kaplan-Meier analysis and computed cumulative hazard functions using Nelson-Aalen function. RESULTS Of 126,408 individuals, 59,989 (47%) and 60,411 (48%) had available data for pathological and clinical-stage OS analysis, respectively. The 3-year OS for AJCC-7 among pathologically staged patients was: stage IA 97%, stage IB 95%, stage IIA 87%, stage IIB 76%, stage IIC 57%, stage IIIA 86%, stage IIIB 69%, stage IIIC 50%, and stage IV 24%. The 3-year OS for AJCC-8 patients was similar but was 56% for stage IIIC and 30% for stage IIID. Stage IV individuals with an elevated LDH had worse OS and CSS at all measured time-points up to 60 months compared to those with a normal LDH. CONCLUSION The discriminatory ability of AJCC-8 and AJCC-7 appear comparable. Changes in AJCC-8 identified stage IIID as a poor prognostic subgroup among stage III patients and elevated LDH in stage IV. However, patients with advanced T-stage, node-negative tumors experienced worse survival compared to those with earlier T-stage, node-positive tumors, and the results of ongoing trials should inform adjuvant therapy in this subset of patients.
Collapse
Affiliation(s)
- Angelina Tjokrowidjaja
- Department of Medical Oncology, St. George Hospital, Kogarah, New South Wales, Australia.,Department of Medical Oncology, Sutherland Hospital, Kogarah, New South Wales, Australia.,National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
| | - Lois Browne
- Department of Radiation Oncology, St. George Hospital, Kogarah, New South Wales, Australia
| | - Hussein Soudy
- Department of Medical Oncology, St. George Hospital, Kogarah, New South Wales, Australia.,Department of Medical Oncology, Sutherland Hospital, Kogarah, New South Wales, Australia.,School of Medicine, University of New South Wales, Kensington, New South Wales, Australia.,Faculty of Medicine, Cairo University, Cairo, Egypt
| |
Collapse
|
2
|
Mitotic Rate as a Prognostic Factor in Melanoma: Implications for Disease Management. ACTAS DERMO-SIFILIOGRAFICAS 2021. [DOI: 10.1016/j.adengl.2021.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
3
|
Bois MC, Morgado-Carrasco D, Barba PJ, Puig S. Mitotic rate as a prognostic factor in melanoma and implications in patient management. ACTAS DERMO-SIFILIOGRAFICAS 2021; 112:S0001-7310(21)00181-2. [PMID: 33992620 DOI: 10.1016/j.ad.2020.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2020] [Revised: 04/28/2020] [Accepted: 05/23/2020] [Indexed: 10/21/2022] Open
Affiliation(s)
- Marina Clara Bois
- Dermatology Department, Hospital General de Agudos Dr. Cosme Argerich, Buenos Aires, Argentina
| | - Daniel Morgado-Carrasco
- Dermatology Department, Melanoma Group IDIBAPS, Hospital Clínic de Barcelona, Universitat de Barcelona, España.
| | - Paula Johana Barba
- Dermatology Department, HIGA Prof. Dr. Rodolfo Rossi, La Plata, Argentina
| | - Susana Puig
- Dermatology Department, Melanoma Group IDIBAPS, Hospital Clínic de Barcelona, Universitat de Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain
| |
Collapse
|
4
|
Zhou S, Sikorski D, Xu H, Zubarev A, Chergui M, Lagacé F, Miller WH, Redpath M, Ghazal S, Butler MO, Petrella TM, Claveau J, Nessim C, Salopek TG, Gniadecki R, Litvinov IV. Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients. Cancers (Basel) 2021; 13:2282. [PMID: 34068774 PMCID: PMC8126223 DOI: 10.3390/cancers13092282] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Revised: 04/26/2021] [Accepted: 04/28/2021] [Indexed: 12/11/2022] Open
Abstract
Targeted therapy has been developed through an in-depth understanding of molecular pathways involved in the pathogenesis of melanoma. Approximately ~50% of patients with melanoma have tumors that harbor a mutation of the BRAF oncogene. Certain clinical features have been identified in BRAF-mutated melanomas (primary lesions located on the trunk, diagnosed in patients <50, visibly pigmented tumors and, at times, with ulceration or specific dermatoscopic features). While BRAF mutation testing is recommended for stage III-IV melanoma, guidelines differ in recommending mutation testing in stage II melanoma patients. To fully benefit from these treatment options and avoid delays in therapy initiation, advanced melanoma patients harboring a BRAF mutation must be identified accurately and quickly. To achieve this, clear definition and implementation of BRAF reflex testing criteria/methods in melanoma should be established so that patients with advanced melanoma can arrive to their first medical oncology appointment with a known biomarker status. Reflex testing has proven effective for a variety of cancers in selecting therapies and driving other medical decisions. We overview the pathophysiology, clinical presentation of BRAF-mutated melanoma, current guidelines, and present recommendations on BRAF mutation testing. We propose that reflex BRAF testing should be performed for every melanoma patient with stages ≥IIB.
Collapse
Affiliation(s)
- Sarah Zhou
- Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada
| | - Daniel Sikorski
- Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada
| | - Honghao Xu
- Division of Dermatology, Laval University, Quebec City, QC G1V 0A6, Canada
| | - Andrei Zubarev
- Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada
| | - May Chergui
- Department of Pathology, McGill University, Montreal, QC H3A 0G4, Canada
| | - François Lagacé
- Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada
| | - Wilson H Miller
- Departments of Medicine and Oncology, McGill University, Montreal, QC H3A 0G4, Canada
| | - Margaret Redpath
- Department of Pathology, McGill University, Montreal, QC H3A 0G4, Canada
| | - Stephanie Ghazal
- Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada
| | - Marcus O Butler
- Princess Margaret Cancer Centre, Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON M5G 2C1, Canada
| | - Teresa M Petrella
- Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
| | - Joël Claveau
- Division of Dermatology, Laval University, Quebec City, QC G1V 0A6, Canada
| | - Carolyn Nessim
- Division of General Surgery, University of Ottawa, Ottawa, ON K1N 6N5, Canada
| | - Thomas G Salopek
- Division of Dermatology, University of Alberta, Edmonton, AB T6G 2R3, Canada
| | - Robert Gniadecki
- Division of Dermatology, University of Alberta, Edmonton, AB T6G 2R3, Canada
| | - Ivan V Litvinov
- Division of Dermatology, McGill University, Montreal, QC H3A 0G4, Canada
| |
Collapse
|
5
|
Hu Y, Briggs A, Marchetti MA, Ariyan CE, Coit DG, Bartlett EK. Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma. J Am Coll Surg 2020; 231:547-554.e1. [PMID: 32889093 PMCID: PMC7854824 DOI: 10.1016/j.jamcollsurg.2020.08.750] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 08/12/2020] [Accepted: 08/12/2020] [Indexed: 01/14/2023]
Abstract
BACKGROUND Indiscriminate use of adjuvant therapy in stage IIIA melanoma is controversial. We sought to model the clinical impact and cost of implementing a gene expression profile (GEP) test to guide adjuvant therapy. STUDY DESIGN A Markov decision-analysis model was created to represent resected stage IIIA melanoma with 3 treatment options: observation (OBS), adjuvant pembrolizumab for all patients (ALL), and selective adjuvant therapy (SEL). In the SEL option, only high-risk patients based on GEP stratification were treated with pembrolizumab. Cost of adjuvant therapy was normalized to reflect Medicare reimbursement schedules. The primary outcome was cost per mortality avoided at 10 years. RESULTS Model projections for 10-year overall survival were 68% for OBS, 73% for SEL, and 76% for ALL. The estimated incremental cost-per-mortality-avoided (compared to OBS) was $2.1 million for SEL and $2.4 million for ALL. These translate to costs of $583.0K and $697.1K per life-year for the SEL and ALL strategies, respectively. CONCLUSIONS Routine adjuvant pembrolizumab for stage IIIA melanoma is costly, and risk-stratification by GEP only marginally improves the value of therapy.
Collapse
Affiliation(s)
- Yinin Hu
- Department of Surgery/Division of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Andrew Briggs
- Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Michael A Marchetti
- Department of Medicine, Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Charlotte E Ariyan
- Department of Surgery/Division of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Daniel G Coit
- Department of Surgery/Division of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
| | - Edmund K Bartlett
- Department of Surgery/Division of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.
| |
Collapse
|
6
|
Miller R, Walker S, Shui I, Brandtmüller A, Cadwell K, Scherrer E. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review. Melanoma Manag 2020; 7:MMT39. [PMID: 32399177 PMCID: PMC7212505 DOI: 10.2217/mmt-2019-0022] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Aim Management of cutaneous melanoma (CM) is continually evolving with adjuvant treatment of earlier stage disease. The aim of this review was to identify published epidemiological data for stages II-III CM. Materials & methods Systematic searches of Medline and Embase were conducted to identify literature reporting country/region-specific incidence, prevalence, survival or mortality outcomes in stage II and/or III CM. Screening was carried out by two independent reviewers. Results & conclusion Of 41 publications, 14 described incidence outcomes (incidence rates per stage were only reported for US and Swedish studies), 33 reported survival or mortality outcomes and none reported prevalence data. This review summarizes relevant data from published literature and highlights an overall paucity of epidemiological data in stages II and III CM.
Collapse
Affiliation(s)
- Rachael Miller
- PHMR Ltd, Berkeley Works, Berkley Grove, Camden Town, London, UK
| | - Sophie Walker
- PHMR Ltd, Berkeley Works, Berkley Grove, Camden Town, London, UK
| | - Irene Shui
- Merck & Co., Inc., Kenilworth, NJ 07033, USA
| | | | - Kevin Cadwell
- PHMR Ltd, Berkeley Works, Berkley Grove, Camden Town, London, UK
| | | |
Collapse
|